The new mid-stage trial will determine whether the vaccine is effective on people between the ages of 6 and 17, according to a statement from the university.

Around 300 volunteers will be enrolled and first inoculations are expected this month, Oxford said.

The two-dose Oxford/AstraZeneca vaccine has been hailed as a ‘vaccine for the world’ because it is cheaper and easier to distribute than some rivals.

AstraZeneca has a target to produce 3 billion doses this year and aims to produce over 200 million doses per month by April.

The post Oxford University to test COVID-19 vaccine response among children for first time appeared first on The Gulf Indians.

He said he believes trials will show his firm has achieved a vaccine efficacy similar to Pfizer BioNTech and Moderna vaccines.

Earlier, several reports suggested that AstraZeneca vaccine may not be as good as the one made by Pfizer, already being distributed in the UK and other countries. Partial results suggest that the AstraZeneca shot is about 70 percent effective for preventing illness from coronavirus infection, compares to the 95% efficacy reported by Pfizer and its German partner BioNTech.

“We think we have figured out the winning formula and how to get efficacy that, after two doses, is up there with everybody else,” the chief executive said, while saying only that data would be published at “some point”.

The United Kingdom government announced on December 23 that the developers of the Oxford-AstraZeneca vaccine had submitted their data to the Medicines and Healthcare products Regulatory Agency (MHRA). Approval is expected to be granted to roll out the jab on January 4.

The Pfizer-BioNTech vaccine was the first coronavirus shot to be authorised for use by the UK’s independent medicines regulator and has been given to 600,000 of the country’s most vulnerable people since last month.

Earlier trials had shown different outcomes in the AstraZeneca shot’s efficacy. The vaccine initially showed an average 70 per cent effectiveness but that level jumped to 90 per cent depending on the dosage.

The post AstraZeneca Covid vaccine claims achieving 100% winning formula appeared first on The Gulf Indians.

A Food and Drug Administration advisory committee is set to meet on December 10 to discuss Pfizer Inc.’s request for an emergency use authorisation for its developing Covid-19 vaccine.

US drug maker Pfizer Inc, has claimed that they developed a 95% effective vaccine against coronavirus. They are now seeking the emergency use tag from US government for its dosage. Pfizer has said the emergency use tag could start the process early and the coronavirus vaccine doses could be available as early as next month.

Dr. Moncef Slaoui, head of Operation Warp Speed, the coronvirus vaccine program said that their plan is able to ship vaccines to the immunisation sites within 24 hours from the approval.

Meanwhile leaders of the 20 biggest economies vowed to spare no effort to supply Covid-19drugs, tests and vaccines affordably and fairly to ‘all people”, reflecting worries that the pandemic could deepen divisions between the world’s rich and poor.

Meanwhile Niti Ayog member and National Expert Group on Vaccine Administration for COVID-19, Vinod Paul said that Pune-based Serum Institute (SII) may be granted emergency use authorisation of the Oxford AstraZeneca coronavirus vaccine if AstraZeneca get approval from the UK government. He also said that if the clinical trials of the coronavirus vaccine in India go as per the script, phase III trials should be over by January-February 2021.

The post First US citizen likely to receive COVID vaccine shot by December 12 appeared first on The Gulf Indians.